Want to see HOWL full AI Analyst Report?
Top Page
Werewolf Therapeutics
(NASDAQ:HOWL)
Select Model
Select Model
Rating:50Neutral
Price Target:
$0.43
▲(0.23% Upside)
Action:Reiterated
Date:08/22/26
The score is held back primarily by weak financial performance (large ongoing losses, persistent cash burn, and a much smaller equity/asset base), partially offset by constructive near-term technical momentum and positive corporate events that strengthen funding runway and strategic focus. Valuation metrics provide limited support due to negative earnings and no dividend.
Positive Factors
Strategic merger and funding runway
The merger brings substantial specialist funding and targets a late-stage development program, potentially reducing near-term financing pressure and enabling operations through pivotal data and a planned regulatory filing.
Negative Factors
Persistent cash burn
Sustained negative cash generation means the company cannot currently fund operations internally. Continued development spending is therefore likely to require financing, partnerships, asset sales, or other external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic merger and funding runway
The merger brings substantial specialist funding and targets a late-stage development program, potentially reducing near-term financing pressure and enabling operations through pivotal data and a planned regulatory filing.
Read all positive factors
Werewolf Therapeutics (HOWL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.45M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue GrowthN/A
EPS Growth55.37%
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.73
Shares Outstanding48,599,068
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.48
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Werewolf Therapeutics Business Overview & Revenue Model
Company Description
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecul...
How the Company Makes Money
Werewolf Therapeutics generates revenue primarily through collaboration and license arrangements common to clinical-stage biotech companies. These agreements can include upfront payments, research and development reimbursements or service revenue,...
Werewolf Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.00M | 0.00 | 1.89M | 19.94M | 16.40M | 0.00 |
| Gross Profit | 18.15M | -1.63M | 71.00K | 18.18M | 13.89M | 0.00 |
| EBITDA | -22.02M | -53.91M | -64.05M | -32.47M | -51.30M | -49.77M |
| Net Income | -34.61M | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M |
Balance Sheet | ||||||
| Total Assets | 24.16M | 69.40M | 126.93M | 174.83M | 160.25M | 179.25M |
| Cash, Cash Equivalents and Short-Term Investments | 21.99M | 57.95M | 111.00M | 134.34M | 129.31M | 157.53M |
| Total Debt | 0.00 | 9.44M | 37.09M | 51.92M | 14.68M | 15.66M |
| Total Liabilities | 7.86M | 44.59M | 53.54M | 63.46M | 37.91M | 26.46M |
| Stockholders Equity | 16.29M | 24.80M | 73.39M | 111.37M | 122.34M | 152.79M |
Cash Flow | ||||||
| Free Cash Flow | -30.15M | -60.29M | -56.44M | -33.38M | -44.21M | -43.37M |
| Operating Cash Flow | -30.15M | -60.29M | -56.19M | -32.61M | -40.60M | -42.88M |
| Investing Cash Flow | 416.00K | 0.00 | -254.00K | -769.00K | -3.61M | -498.00K |
| Financing Cash Flow | -26.77M | 6.03M | 13.08M | 58.43M | 15.91M | 109.43M |
Werewolf Therapeutics Technical Analysis
Positive
0.43
Price Trends
0.39
Positive
0.53
Positive
0.66
Positive
Market Momentum
0.04
Negative
86.46
Negative
78.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOWL, the sentiment is Positive. The current price of 0.43 is below the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.39, and below the 200-day MA of 0.66, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 86.46 is Negative, neither overbought nor oversold. The STOCH value of 78.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOWL.
Werewolf Therapeutics Risk Analysis
Werewolf Therapeutics disclosed 89 risk factors in its most recent earnings report. Werewolf Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Werewolf Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $281.13M | -2.01 | -314.08% | ― | 40.21% | 13.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $42.45M | -1.19 | -166.98% | ― | ― | 55.37% | |
49 Neutral | $154.13M | -4.79 | 168.68% | ― | ― | 67.07% | |
48 Neutral | $90.64M | -2.05 | -71.71% | ― | ― | 73.44% | |
46 Neutral | $39.61M | -0.82 | -156.02% | ― | -95.74% | -23.18% |
* Healthcare Sector Average
HOWL
Werewolf Therapeutics
0.87
-0.50
-36.28%
CRVO
CervoMed
2.62
-6.81
-72.22%
NRXP
NRX Pharmaceuticals
3.56
0.87
32.34%
KLRS
Kalaris Therapeutics
4.15
1.64
65.34%
CAMP
CAMP4 Therapeutics Corporation
4.48
2.92
187.18%
Werewolf Therapeutics Corporate Events
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Werewolf Therapeutics to Merge and Rebrand as Ambros
Positive
Aug 21, 2026
On August 21, 2026, Werewolf Therapeutics and Ambros Therapeutics signed a definitive all‑stock merger agreement under which Ambros will become a wholly owned subsidiary and the combined entity, renamed Ambros Therapeutics, will focus on adv...
Business Operations and StrategyM&A Transactions
Werewolf Therapeutics Monetizes Platforms, Refocuses on Lead Programs
Positive
Aug 20, 2026
On August 14, 2026, Werewolf Therapeutics entered into an asset purchase agreement with EMD Serono Research Development Institute under which it sold its pre-clinical INDUCER platform and portions of its INDUKINE platform, including associated pa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.